Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MicroPort CRM
The study will focus on the number of patients moving to persistent Atrial Fibrillation as a function of cumulative %Vp (\< or \>40%), in a general dual-chamber pacemaker population through a 2 year follow-up (n=2188).
The same endpoint will be analyzed in sub populations (Sinus Node Disease and AVB) at 4 years follow up (n=4290).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Patient implanted (primo-implant, replacement, upgrade) with dual chamber pacemaker from less than two months or implanted at inclusion.
You may not be if
Contraindicated for cardiac pacing, according to the ESC and ACC/AHA/HRS guidelines
Permanent or persistent atrial tachyarrhythmia
Clareo Health | EMERALD - AssEssment of CoMorbidities & Atrial ArRhythmiA Burden in DuaL-Chamber PaceD Patients
